Related Articles
N-803/BCG Approval Signals Paradigm Shift in Management of BCG-Unresponsive NMIBC
Karim Chamie, MD, discusses the significance of the FDA approval of N-803 plus BCG in BCG-unresponsive non–muscle invasive bladder cancer.
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study
Once-monthly garadacimab for more than 2 years in patients with hereditary angioedema was well tolerated and efficacious in reducing monthly attack rate and improving HRQoL.…
IDHENTIFY trial: Impact of mutational burden and pattern on outcomes in patients with R/R IDH2-mutated AML
Here, we summarize a post hoc analysis of the IDHENTIFY trial investigating the molecular characteristics and prognostic impact of co-occurring mutations in patients with R/R…
The real-world safety and efficacy of CPX-351 in patients with AML
Priyanka Mehta, MBBS, MD, FRCP, FRCPath, University Hospitals Bristol NHS Foundation Trust, Bristol, UK, briefly discusses the real-world safety and efficacy data collected when using…
When leukaemia masquerades: the hidden syphilis diagnosis
A 61-year-old man with chronic lymphocytic leukaemia maintained on oral venetoclax 400 mg daily presented to the emergency department with oral lesions, worsening lymphadenopathy, and…
Prostate cancer hope as patients could get painless treatment instead of chemo
Currently patients with a form of the disease which has spread to one or two other parts of the body are assumed to be resistant…
New trial finds radiotherapy combined with hormone therapy can help s
Radiotherapy can be used alongside hormone treatment, delaying the need for chemotherapy and therefore significantly protecting their quality of life for some patients with advanced…
Adjuvant Multipeptide Vaccine Combination Prolongs Survival in Melanoma
A multipeptide vaccine combination approach with 12MP plus 6MHP vs 12MP plus tet extended overall survival in patients with stage IIB to IV melanoma.
AAN: Monoclonal Antibodies for MS During Breastfeeding Not Harmful
No association seen for mAb during breastfeeding with infant hospitalization, systemic antibiotic use, developmental delay.
Eftilagimod Alpha Novel Triplet Combination is Well Tolerated, Generates CRs in Soft Tissue Sarcoma
Eftilagimod alpha plus radiotherapy and pembrolizumab was safe and displayed initial activity in soft tissue sarcoma.